Literature DB >> 27752872

Retention, Antiretroviral Therapy Use and Viral Suppression by History of Injection Drug Use Among HIV-Infected Patients in an Urban HIV Clinical Cohort.

Catherine R Lesko1, Weiqun Tong2, Richard D Moore2,3, Bryan Lau2,3.   

Abstract

Compared to HIV-infected persons who do not inject drugs (non-IDU), persons who inject drugs (PWID) experience disparities in linking to medical care, initiating antiretroviral therapy (ART) and achieving viral suppression. There has been little attention to changes in these disparities over time. We estimated the proportion of PWID and non-IDU retained in care, on ART, and virally suppressed each year from 2001-2012 in the Johns Hopkins HIV Clinical Cohort (JHHCC). We defined active clinic patients as those who had ≥1 clinical visit, CD4 cell count, or viral load between July 1 of the prior year, and June 30 of the analysis year. Within a calendar year, retention was defined as ≥2 clinical visits or HIV-related laboratory measurements >90 days; ART use was defined as ≥1 ART prescription active ≥30 days; and viral suppression was defined as ≥1 HIV viral load <400 copies/mL. While PWID were less likely to be retained in earlier years, the gaps in retention closed around 2010. After 2003-2004, PWID and non-IDU retained in care had similar probability of receiving a prescription for ART and PWID and non-IDU on ART had similar probability of viral suppression.

Entities:  

Keywords:  Antiretroviral therapy; HIV care continuum; Injection drug use; Viral load suppression

Mesh:

Substances:

Year:  2017        PMID: 27752872      PMCID: PMC5344751          DOI: 10.1007/s10461-016-1585-5

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  29 in total

1.  Marginal structural models as a tool for standardization.

Authors:  Tosiya Sato; Yutaka Matsuyama
Journal:  Epidemiology       Date:  2003-11       Impact factor: 4.822

2.  Fighting HIV/AIDS in Washington, D.C.

Authors:  Alan E Greenberg; Shannon L Hader; Henry Masur; A Toni Young; Jennifer Skillicorn; Carl W Dieffenbach
Journal:  Health Aff (Millwood)       Date:  2009 Nov-Dec       Impact factor: 6.301

3.  Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy.

Authors:  K E Poundstone; R E Chaisson; R D Moore
Journal:  AIDS       Date:  2001-06-15       Impact factor: 4.177

4.  The cascade of HIV care in British Columbia, Canada, 1996-2011: a population-based retrospective cohort study.

Authors:  Bohdan Nosyk; Julio S G Montaner; Guillaume Colley; Viviane D Lima; Keith Chan; Katherine Heath; Benita Yip; Hasina Samji; Mark Gilbert; Rolando Barrios; Réka Gustafson; Robert S Hogg
Journal:  Lancet Infect Dis       Date:  2013-09-27       Impact factor: 25.071

5.  Measuring retention in HIV care: the elusive gold standard.

Authors:  Michael J Mugavero; Andrew O Westfall; Anne Zinski; Jessica Davila; Mari-Lynn Drainoni; Lytt I Gardner; Jeanne C Keruly; Faye Malitz; Gary Marks; Lisa Metsch; Tracey E Wilson; Thomas P Giordano
Journal:  J Acquir Immune Defic Syndr       Date:  2012-12-15       Impact factor: 3.731

6.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Authors:  S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

7.  Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001.

Authors:  Kelly A Gebo; John A Fleishman; Richard Conviser; Erin D Reilly; P Todd Korthuis; Richard D Moore; James Hellinger; Philip Keiser; Haya R Rubin; Lawrence Crane; Fred J Hellinger; W Christopher Mathews
Journal:  J Acquir Immune Defic Syndr       Date:  2005-01-01       Impact factor: 3.731

8.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

9.  Retention among North American HIV-infected persons in clinical care, 2000-2008.

Authors:  Peter Rebeiro; Keri N Althoff; Kate Buchacz; John Gill; Michael Horberg; Hartmut Krentz; Richard Moore; Timothy R Sterling; John T Brooks; Kelly A Gebo; Robert Hogg; Marina Klein; Jeffrey Martin; Michael Mugavero; Sean Rourke; Michael J Silverberg; Jennifer Thorne; Stephen J Gange
Journal:  J Acquir Immune Defic Syndr       Date:  2013-03-01       Impact factor: 3.731

10.  A longitudinal, HIV care continuum: 10-year restricted mean time in each care continuum stage after enrollment in care, by history of IDU.

Authors:  Catherine R Lesko; Jessie K Edwards; Richard D Moore; Bryan Lau
Journal:  AIDS       Date:  2016-09-10       Impact factor: 4.177

View more
  12 in total

Review 1.  Challenges Facing a Rural Opioid Epidemic: Treatment and Prevention of HIV and Hepatitis C.

Authors:  Asher J Schranz; Jessica Barrett; Christopher B Hurt; Carlos Malvestutto; William C Miller
Journal:  Curr HIV/AIDS Rep       Date:  2018-06       Impact factor: 5.071

2.  Methamphetamine use drives decreases in viral suppression for people living with HIV released from a large municipal jail: Results of the LINK LA clinical trial.

Authors:  David Goodman-Meza; Steve Shoptaw; Robert E Weiss; Terry Nakazono; Nina T Harawa; Sae Takada; Wendy H Garland; William E Cunningham
Journal:  Drug Alcohol Depend       Date:  2019-07-16       Impact factor: 4.492

3.  Comparative Clinical Outcomes With Scale-up of Dolutegravir as First-Line Antiretroviral Therapy in Ukraine.

Authors:  Kostyantyn Dumchev; Tetiana Kiriazova; Serhiy Riabokon; Alyona Shost; Canada Parrish; Anna Shapoval; Myroslava Germanovych; Jeremy Penner; Jason Beste; Nancy Puttkammer
Journal:  J Acquir Immune Defic Syndr       Date:  2022-10-01       Impact factor: 3.771

4.  Influence of Injection Drug Use-Related HIV Acquisition on CD4 Response to First Antiretroviral Therapy Regimen Among Virally Suppressed Individuals.

Authors:  Keri L Calkins; Catherine R Lesko; Geetanjali Chander; Richard D Moore; Bryan Lau
Journal:  J Acquir Immune Defic Syndr       Date:  2018-03-01       Impact factor: 3.731

5.  An application of agent-based modeling to explore the impact of decreasing incarceration rates and increasing drug treatment access on sero-discordant partnerships among people who inject drugs.

Authors:  Sabriya L Linton; Don C Des Jarlais; Joseph T Ornstein; Matt Kasman; Ross Hammond; Behzad Kianian; Justin C Smith; Mary E Wolfe; Zev Ross; Danielle German; Colin Flynn; Henry F Raymond; R Monina Klevens; Emma Spencer; John-Mark Schacht; Teresa Finlayson; Gabriela Paz-Bailey; Cyprian Wejnert; Hannah L F Cooper
Journal:  Int J Drug Policy       Date:  2021-03-31

6.  Changing Patterns of Alcohol Use and Probability of Unsuppressed Viral Load Among Treated Patients with HIV Engaged in Routine Care in the United States.

Authors:  Catherine R Lesko; Robin M Nance; Bryan Lau; Anthony T Fojo; Heidi E Hutton; Joseph A C Delaney; Heidi M Crane; Karen L Cropsey; Kenneth H Mayer; Sonia Napravnik; Elvin Geng; W Christopher Mathews; Mary E McCaul; Geetanjali Chander
Journal:  AIDS Behav       Date:  2020-10-16

7.  HIV cascade of care in Greece: Useful insights from additional stages.

Authors:  Georgia Vourli; Georgios Nikolopoulos; Vasilios Paparizos; Athanasios Skoutelis; Symeon Metallidis; Panagiotis Gargalianos; Antonios Papadopoulos; Maria Chini; Nikolaos V Sipsas; Mina Psychogiou; Georgios Chrysos; Helen Sambatakou; Charalambos Gogos; Olga Katsarou; Dimitra Paraskeva; Nikos Dedes; Giota Touloumi
Journal:  PLoS One       Date:  2018-11-15       Impact factor: 3.240

8.  Self-efficacy as a mediator of patient navigation interventions to engage persons living with HIV and substance use.

Authors:  Sharleen M Traynor; Lisa R Metsch; Lauren Gooden; Maxine Stitzer; Tim Matheson; Susan Tross; Adam W Carrico; Mamta K Jain; Carlos Del Rio; Daniel J Feaster
Journal:  Drug Alcohol Depend       Date:  2021-02-03       Impact factor: 4.492

9.  Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?

Authors:  Georgia Vourli; Teymur Noori; Anastasia Pharris; Kholoud Porter; Maria Axelsson; Josip Begovac; Francoise Cazein; Dominique Costagliola; Susan Cowan; Sara Croxford; Antonella d'Arminio Monforte; Valerie Delpech; Asunción Díaz; Enrico Girardi; Barbara Gunsenheimer-Bartmeyer; Victoria Hernando; Gisela Leierer; Florence Lot; Olivier Nunez; Niels Obel; Eline Op de Coul; Dimitra Paraskeva; Stavros Patrinos; Peter Reiss; Daniela Schmid; Anders Sonnerborg; Barbara Suligoi; Virginie Supervie; Ard van Sighem; Robert Zangerle; Giota Touloumi
Journal:  Clin Infect Dis       Date:  2020-12-31       Impact factor: 9.079

10.  The Effect of Buprenorphine on Human Immunodeficiency Virus Viral Suppression.

Authors:  Jongyeon Kim; Catherine R Lesko; Anthony T Fojo; Jeanne C Keruly; Richard D Moore; Geetanjali Chander; Bryan Lau
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 20.999

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.